Apollo Therapeutics is about to find out if its novel portfolio-building approach to biotech can pay off, starting with a Phase II readout from its IL-18 candidate in atopic dermatitis.
The UK-headquartered company has been around since 2015 and works with the country’s universities to translate breakthroughs in basic science...